Using the bootstrap to establish statistical significance for relative validity comparisons among patientreported outcome measures
 Nina Deng^{1}Email author,
 Jeroan J Allison^{1},
 Hua Julia Fang^{1},
 Arlene S Ash^{1} and
 John E WareJr^{1, 2}
DOI: 10.1186/147775251189
© Deng et al.; licensee BioMed Central Ltd. 2013
Received: 21 February 2013
Accepted: 27 May 2013
Published: 31 May 2013
Abstract
Background
Relative validity (RV), a ratio of ANOVA Fstatistics, is often used to compare the validity of patientreported outcome (PRO) measures. We used the bootstrap to establish the statistical significance of the RV and to identify key factors affecting its significance.
Methods
Based on responses from 453 chronic kidney disease (CKD) patients to 16 CKDspecific and generic PRO measures, RVs were computed to determine how well each measure discriminated across clinicallydefined groups of patients compared to the most discriminating (reference) measure. Statistical significance of RV was quantified by the 95% bootstrap confidence interval. Simulations examined the effects of sample size, denominator Fstatistic, correlation between comparator and reference measures, and number of bootstrap replicates.
Results
The statistical significance of the RV increased as the magnitude of denominator Fstatistic increased or as the correlation between comparator and reference measures increased. A denominator Fstatistic of 57 conveyed sufficient power (80%) to detect an RV of 0.6 for two measures correlated at r = 0.7. Larger denominator Fstatistics or higher correlations provided greater power. Larger sample size with a fixed denominator Fstatistic or more bootstrap replicates (beyond 500) had minimal impact.
Conclusions
The bootstrap is valuable for establishing the statistical significance of RV estimates. A reasonably large denominator Fstatistic (F > 57) is required for adequate power when using the RV to compare the validity of measures with small or moderate correlations (r < 0.7). Substantially greater power can be achieved when comparing measures of a very high correlation (r > 0.9).
Keywords
Bootstrap Relative validity Analysis of variance (ANOVA) Confidence interval Patientreported outcome (PRO) measure Chronic kidney disease (CKD)Introduction
There has been an increasingly widespread application of patientreported outcome (PRO) measures in assessing the outcomes of healthrelated quality of life. Along with the noteworthy improvements in measurement theory, advances in data capture and processing technologies, and various approaches to generic and diseasespecific measures, there are more available choices among PRO measurement tools than ever before. Relative Validity (RV), also referred to as relative precision or relative efficiency [1]–[3], provides an appropriate quantitative index to compare the validity of PRO measures under the conditions in which such measures are typically used. As such, the RV compares two PRO measures on their ability to discriminate patients across disease severity levels and on their ability to detect longitudinal change [4]–[6]. Complementary to other psychometric properties such as reliability and respondent burden, the RV is used frequently in literature providing important validity information of PRO measures.
A noteworthy limitation of the RV, which we address in this study, is the absence of a basis for establishing its statistical significance and an understanding of the factors affecting that significance. The common practice is to compute the RV and simply conclude that the comparator measure has more (or less) discriminating power or responsiveness than the reference measure if the RV is greater (or less) than 1. However, an RV may differ from the null value of 1 because of the random error in the absence of “true” differences among the measures being compared. Therefore, establishing the statistical significance of the RV is necessary for identifying “true” differences in validity between PRO measures.
In spite of this need, the statistical significance of the RV is typically not discussed, likely because its underlying probability distribution is not easily derived analytically. The bootstrap, a wellknown statistical technique for estimating the confidence interval based on an empirical distribution without assuming a probability distribution, offers a promising solution [7]–[10]. This technique, however, has not yet been widely applied to the RV. Therefore, we evaluated the bootstrap as a technique for statistically testing the RV and, furthermore, used simulations to investigate factors that may affect the bootstrap confidence intervals of the RV under different conditions.
Methods
Description of the data
Secondary data analyses were conducted using the responses of 453 chronic kidney disease (CKD) patients to sixteen CKDspecific and generic PRO measures. The 16 measures included (a) three widelyused CKDspecific legacy scales: the Kidney Disease Quality of Life (KDQOL) Burden, Symptoms, and Effects scales [11]; (b) eight generic profile scales that are widely used in CKD: the Medical Outcomes Study ShortForm 12 (SF12) with Physical Functioning (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Emotional (RE), and Mental Health (MH); (c) two generic summary scales included in the SF12: Physical Component Summary (PCS) and Mental Component Summary (MCS) [12]; and (d) three varyinginlength forms of the newly developed Qualityoflife Disease Impact Scale for CKD (QDISCKD) [13, 14]: the original 34item form – Static34, a shorter 6item form – Static6, and a computer adaptive testing (CAT) form with five dynamic items – CAT5. The 16 measures were chosen to allow comparison of widelyused generic and CKDspecific measures and to compare new measures with the legacy measures. External clinicallydefined disease states were used to classify the patients into three ANOVA groups: dialysis (n = 206), predialysis stage 35 (n = 113), and transplant (n = 134) [15]–[17]. The study was approved by the New England Institutional Review Board (NEIRB 06058). Patients were fully informed and consent was obtained.
Relative validity
The relative validity (RV) is defined as a ratio of ANOVA Fstatistics, with the Fstatistic of the comparator measure taken as the numerator and the Fstatistic of the reference measure taken as the denominator. An RV greater than 1 indicates that the comparator measure has greater discriminating power or responsiveness than the reference measure, and vice versa. This approach for validating PRO measures is also called the “knowngroups method” [18] because the Fstatistic is obtained by comparing groups known to differ based on external criteria, e.g., clinicallydefined diagnosis or severity. We prefer the term relative validity because separation between known groups as measured by the Fstatistic is the essence of validity. In addition to comparing different PRO measures, the RV is also widely used for comparing different scoring methods for the same PRO measure, e.g., the classical summed score versus the score based on modern psychometric models such as the item response theory (IRT) models [19]–[23].
ANOVAbased Fstatistic and relative validity for CKDspecific and generic PRO measures across clinicallydefined groups (N = 453)
PRO measure  Dialysis  Predialysis stage 35  Transplant  r^{ b }(total)  Fstatistic  RV  95% CI ^{c}  

(n = 206)  (n = 113)  (n = 134)  
Mean  (SD)  r ^{a}  Mean  (SD)  r ^{a}  Mean  (SD)  r ^{a}  
CKDspecific  
QDISCKD  
CAT5  39.83  (22.17)  1  16.19  (21.51)  1  19.25  (21.63)  1  1  57.43^{**}  1   
Static6  39.18  (22.86)  0.91  16.86  (21.84)  0.96  19.60  (21.29)  0.93  0.94  50.15^{**}  0.87  (0.721.03) 
Static34  35.93  (21.23)  0.93  14.90  (20.05)  0.96  18.71  (20.52)  0.95  0.95  48.01^{**}  0.84  (0.710.97) 
KDQOL  
Burden  48.83  (26.81)  0.60  76.62  (24.76)  0.73  68.21  (28.90)  0.77  0.74  44.46^{**}  0.77  (0.531.09) 
Symptoms  71.95  (16.23)  0.57  80.58  (15.80)  0.65  80.03  (15.96)  0.66  0.65  15.11^{**}  0.26  (0.130.44) 
Effects  63.41  (21.92)  0.54  84.38  (17.59)  0.79  77.86  (20.18)  0.73  0.71  43.95^{**}  0.77  (0.521.10) 
Generic  
SF12  
PF  37.06  (10.75)  0.52  45.38  (11.12)  0.57  44.88  (10.69)  0.65  0.63  31.12^{**}  0.54  (0.320.85) 
RP  38.00  (9.41)  0.65  45.12  (9.78)  0.61  45.83  (9.91)  0.63  0.69  34.12^{**}  0.59  (0.380.89) 
BP  43.19  (11.67)  0.47  46.71  (11.27)  0.53  47.10  (11.66)  0.49  0.50  5.84^{**}  0.10  (0.020.22) 
GH  39.08  (11.19)  0.47  41.99  (10.11)  0.51  43.71  (10.93)  0.56  0.52  7.79^{**}  0.14  (0.040.28) 
VT  45.72  (9.25)  0.44  46.40  (10.15)  0.46  48.35  (9.93)  0.48  0.44  3.04^{*}  0.05  (0.000.15) 
SF  42.75  (11.79)  0.65  47.81  (11.25)  0.61  47.83  (10.78)  0.60  0.64  11.02^{**}  0.19  (0.070.34) 
RE  44.59  (11.64)  0.52  48.39  (10.05)  0.49  48.39  (9.76)  0.42  0.51  7.01^{**}  0.12  (0.030.25) 
PCS  36.60  (10.29)  0.54  43.49  (10.37)  0.56  44.08  (10.72)  0.66  0.64  26.61^{**}  0.46  (0.270.74) 
MCS^{d}  49.74  (10.38)  0.49  50.42  (9.57)  0.45  50.55  (9.94)  0.32  0.40  0.32     
MH^{d}  49.85  (10.39)  0.43  50.71  (10.25)  0.49  50.31  (9.95)  0.33  0.38  0.26     
Bootstrap technique
We used bootstrap technique to estimate the standard error (SE) and 95% confidence interval (CI) for the RVs [20]–[26]. The bootstrap is a statistical technique for estimating the accuracy of an estimator and is available in many commonly used statistical software packages. Under the assumption that the empirical distribution of the observed data well represents the true population distribution, the bootstrap technique randomly resamples with replacement the empirical distribution with the sample size equal to the empirical sample size. This technique thus creates multiple “bootstrap replicate” samples, and then computes the RV for each replicate to approximate the sampling distribution of the RV. The standard deviation of RVs from the bootstrap replicates becomes the standard error of the RV estimate, indicating the size of uncertainty (error) in the point estimate of the RV. The 2.5^{th} and 97.5^{th} percentiles of the bootstrap distribution of the RV provide the basis for the 95% confidence interval (CI), which is a range designed to capture with 95% probability the “true” value of RV. Statistical significance of the RV is implied by 95% confidence intervals that exclude the null value of 1.
There are several types of bootstrap confidence intervals available, e.g., the normal, percentile, and biascorrected intervals, etc. The biascorrected and accelerated (BCa) interval is generally considered superior to other methods and therefore was chosen for this study [27]. The BCa interval computes an adjusted percentile confidence interval that accounts for the possible bias of the bootstrap distribution introduced by the resampling process and the variable variance of the bootstrap replicates [28]. In addition, under the circumstances that the bootstrap distributions are potentially biased and skewed, the relationship between the bootstrap standard error and the BCa interval is not quite straightforward; therefore, we reported both the bootstrap standard error and the BCa interval as the complementary information to evaluate the accuracy of RV estimates.
Simulation studies
It is rather intuitive that an RV of 0.3 would more likely be detected as significantly different from the null value of 1 than an RV of 0.6. However, we lack an understanding of the conditions which might cause a given RV to be statistically significant in one study but not in another. Therefore, simulations were conducted to evaluate the potential effects of various factors on the bootstrap results of the RV. Four important factors were manipulated and investigated : (1) sample size (N = 100, 200, 300, 453, 600, 1000, and 2000), (2) magnitude of the Fstatistic for the reference measure (F = 12.6, 25.4, 38.0, 57.4, 76.1, 126.8, and 253.6), (3) magnitude of correlation between the comparator and the reference measure ( r = 0, 0.3, 0.5, 0.7, 0.9, and 0.95), and (4) number of bootstrap replicates (B = 500, 1000, and 2000). Factors not varied were retained as found in the original sample. Each study is described in more detail below.
Sample size
We initially suspected that the sample size would play a prominent role in determining the bootstrap confidence interval of the RV. Seven sample sizes were examined: N = 100, 200, 300, 453, 600, 1000 and 2000, where 453 was the original data sample size. Group means, standard deviations, and correlations between the comparator and reference measure were retained as in the original dataset, as well as the proportion of patients in the three clinical groups (45%, 25% and 30% respectively). It is worthy of note that for a given data set, by definition, the Fstatistic increases as the sample size increases with constant group means and standard deviations. For example, the Fstatistics of the reference measure (QDISCKD CAT5) were 12.6, 25.4, 38.0, 57.4, 76.1, 126.8, and 253.6 for the seven proposed sample sizes, respectively.
The situation does arise in which we want to assess the effects of sample size independent of the Fstatistic. For example, when we evaluate the RVs computed in two data sets, a larger sample size does not necessarily translate into a larger Fstatistic because of differences in group means and standard deviations. Yet, we would still be interested in knowing whether the larger sample size produces a more precise RV estimate. For this reason, we used a second design to assess the effects of sample size while holding the Fstatistic constant. To implement this approach, we let N^{*} denote the desired sample size in the simulated data, N denote the original sample size, and T = N / N^{*}. By multiplying the group standard deviation by 1/√T and keeping the group mean constant, the Fstatistic remained fixed at the values observed in the original data (see Table 1) across the different sample sizes. In particular, the Fstatistic of reference measure (QDISCKD CAT5) was fixed at 57.4, as found in the original data. Because the Fstatistic remained fixed for all PRO measures, the RVs were held constant across the simulated sample size conditions.
Fstatistic of reference measure (denominator Fstatistic)
Beyond the sample size, we suspected that the magnitude of the denominator Fstatistic of the RV would play an important role in determining the statistical significance. Consider four PRO measures A, B, C and D with Fstatistics of 60, 100, 6, and 10, respectively. We suspected that the difference between measures A and B would be more significant than the difference between measures C and D, although both comparisons yield RV = 0.6. The hypothesis was that, given equal RVs, a greater Fstatistic for the reference measure would be associated with a smaller standard error and a greater power.
To test this hypothesis, we simulated data with different Fstatistics but a fixed sample size, so that the effect of the magnitude of Fstatistic could be examined separately. Similar to the design described above, we let F^{*} denote the desired Fstatistic in the simulated data, F denote the Fstatistic observed in the original data, and T^{*} = F^{*} / F. By multiplying the group standard deviation by 1/√T^{*} and keeping the sample size and group mean constant, the Fstatistics changed by a factor of T^{*}. To promote convenient comparisons, data were generated with Fstatistics corresponding to those obtained in the first design of the sample size condition (e.g., the Fstatistics of reference measure were simulated at 12.6, 25.4, 38.0, 57.4, 76.1, 126.8, and 253.6, respectively). In agreement with the original data, the total sample size was fixed at 453. Note that because the Fstatistic changed by the same factor of T^{*} for all PRO measures, the RVs were again held constant across the simulated conditions of Fstatistics.
Correlation between comparator and reference measures
We noted moderate to high correlations among the PRO measures in the study. Furthermore, it seemed appropriate to assume moderate correlations between measures developed for very similar concepts, and even higher correlations between measures sharing common questions (e.g., short and long forms). Specifically, the alternative forms of QDISCKD (Static6 and Static34) were more highly correlated with the reference measure of QDISCKD CAT5 than the scales of KDQOL or SF12 (Table 1). Additionally, we observed that the RV for QDISCKD Static34 (RV = 0.84) was statistically significant while the RVs for KDQOL Burden and for KDQOL Effects (both equal to 0.77) were not, despite the latter being further from the null value of 1. This suggested that a greater correlation between the comparator and the reference measure may lead to greater precision in the RV estimate.
To test this hypothesized effect of correlation, data were generated with a wide range of correlations between the comparator and the reference measures: r = 0, 0.3, 0.5, 0.7, 0.9 and 0.95. The withingroup correlations were assumed equal across the three severity groups. Group means, standard deviations, and sample sizes were maintained constant as in the original data. Again, the RVs for all PRO measures were held constant across the different conditions of correlations.
Number of bootstrap replicates
How many bootstrap replicates are needed in practice to compute stable 95% confidence intervals for the RV statistic? Efron and Tibshirani [27] suggested 200 for calculating the bootstrap standard error but 1000 or more for computing the bootstrap confidence interval. Some researchers have suggested even larger numbers [9]. Because the BCa interval is computationally intensive, minimizing the number of bootstrap replicates might convey practical benefits. Three batches of bootstrap replicates (B = 500, 1000, 2000) were tested. Group sample sizes, means, standard deviations and correlations were all kept constant as in the original data.
Simulation steps
 1.
Generate response data from a bivariate normal distribution for each ANOVA group and for each pair of comparator and reference measures. Using the underlying assumption for ANOVA and Fstatistic, we thus simulated the data from the normal distribution.
 2.
Repeat Step 1 for 100 times to establish 100 simulation datasets for each study condition.
 3.
For each simulation dataset, calculate the bootstrap standard error and the 95% bootstrap confidence interval for the RVs.
 4.
Calculate the average bootstrap standard error, the average 95% bootstrap confidence interval, and the proportion of significant RVs (the “power”) across the 100 simulation datasets.
Results
Bootstrap standard error
Bootstrap confidence interval and power
Simulated distribution of RV estimates
Number of bootstrap replicates
Conclusions
This study demonstrated that the RV, which is often used to compare the validity of alternative PRO measures, may be statistically tested via the bootstrap confidence interval. Simulations identified two key factors affecting whether a given RV represents a statistically significant finding: the magnitude of the denominator Fstatistic (the Fstatistic for the reference measure), and the correlation between the comparator and the reference measure. Although, we found that a lager sample size with a fixed denominator Fstatistic had limited impact on the precision of the RV estimate, it is noteworthy that for a given data set (assuming constant group means and standard deviations), increasing the sample size would produce greater power by naturally increasing the denominator Fstatistic. However, we need to be careful when evaluating RVs calculated in different datasets, where a larger data set may not necessarily have a larger denominator Fstatistic, and thus may not provide greater power.
More specifically, our study suggested that a denominator Fstatistic as low as 13 had very limited power to detect meaningful differences in the RVs. A denominator Fstatistic as large as 57 conveyed sufficient power (80%) to detect a moderate RV of 0.6, given that the measures were correlated at r = 0.7. Furthermore, we found that a greater correlation between the comparator and reference measures with the same denominator Fstatistic provided greater power to detect the differences in the RVs. Based on the reduction in the bootstrap standard error (Figure 1.c) and the increase in power (Figure 3.c), we classified the correlation as small (r ≤ 0.5), moderate (0.5 < r ≤ 0.7), high (0.7 < r ≤ 0.9), or very high (r > 0.9). We also note that a very high correlation is associated with substantial gain in precision and power of the RV estimate.
Discussion
This study has important implications for studies using the RV to compare the validity of PRO measures. First, this work demonstrates the importance of calculating the confidence interval and determining statistical significance of the RV when comparing the validity of PRO measures. Second, our findings suggest that RVs of equal size but calculated under different comparison conditions have distinct statistical implications and should be interpreted differently. A review of about 40 articles published in three relevant journals (Journal of Clinical Epidemiology, Medical Care, and Quality of Life Research) between 1990 and 2012 revealed that the circumstances under which the RV was computed varied widely. The sample size per ANOVA group ranged broadly from 42 to near 4000 [32, 33], the Fstatistic of reference measure ranged widely from less than 4 to over 400 [12, 24], and the correlation between the comparator and reference measures was rarely reported. We suspect that most studies, without constructing a confidence interval for the RV estimate, overinterpreted the observed differences in the RVs with small denominator Fstatistics, ignoring the possibility of falsely rejecting the null hypothesis of no difference when only chance was in operation. On the other hand, “small” but possibly meaningful and statistically significant differences may have been overlooked.
This work also has important implication for designing future studies using the RV. In planning for power calculations in such studies, we suggest that researchers begin with reasonable estimates of the correlation between the comparator and reference measures along with the ANOVA group means and standard deviations. Armed with these estimates, the investigators will better understand how to control the sample size to achieve a desired magnitude of denominator Fstatistic for sufficient power. The effect of correlation between measures on the RV is important given that there is an increasing interest in developing more “efficient” forms from the same item bank [34]. Thus, it becomes very realistic to assume that the PRO measures with the same questions but varying in length are very highly correlated (r > 0.9) for the same group of respondents, as the alternative forms of QDISCKD (CAT5, Static6, and Static34) presented in our current study. Furthermore, it seems reasonable to assume at least moderate correlations (r > 0.5) for measures assessing similar concepts but having different questions, such as the different CKDspecific measures, or the CKDspecific and generic measures with common domains. Our findings also suggest lower correlations (r < 0.5) for measures of distinct domains, such as the physical and mental health.
All confidence intervals in this study were based on the biascorrected and accelerated (BCa) bootstrap method. Generally, there is wide consensus that this method is preferred over other methods [27]. However, there are a few caveats. First, if the acceleration parameter is small (< 0.025), then some simulations suggest that coverage of the BCa interval may be erratic. Second, if there is no bias, meaning that the bootstrap distribution is not skewed and the center of the bootstrap distribution is very close to the center of the observed distribution, bias correction may decrease the precision and unnecessarily increase the width of the BCa interval [35]. Therefore, under the circumstances of no bias and minimal acceleration, the percentilebased confidence interval may offer some advantage. However, we would urge caution because these "ideal" circumstances are not likely to be found in real studies. In fact, we found important bias and substantial acceleration factors in our bootstrap simulations.
This study has specific limitations worth consideration. First, the simulations were based on one data set of PRO measures administered to CKD patients. Nevertheless, it is expected that the findings could be generalizable to PRO measures in other conditions. That said, validations using different samples and conditions are desired. In addition, we limited the number of simulation replications to 100 for most simulation conditions. Selected comparisons were made with a much larger number of simulation replications, and similar results were found. Finally, we selected the reference measure which had the largest Fstatistics and thus limited the values of RVs below the null value of 1. Nevertheless, the statistical significance of the RV should not be affected by the choice of the reference measure, and we would like to further investigate this in the future. Out next and followup plan is to have a more comprehensive study with additional conditions and data sets. It is hoped that such a comprehensive simulation study will provide some practical guidance with a lookup table suggesting minimum denominator Fstatistics required for sufficient power to detect a range of RVs (both below and above 1) under varying circumstances (e.g., measures with different degrees of correlations).
It is noteworthy that the methodology of the RV proposed in the study is appropriate only when the assumptions of ANOVA are met. These assumptions include independent observations, normally distributed dependent variable within groups, and homogeneity of variances across groups. That stated, it is also well recognized that ANOVA is quite robust to deviations from normality and violations of homogeneous variance [36, 37]. To implement this methodology, it would be ideal to have all respondents complete all measures being compared, as in our current study. However, in longer surveys this could greatly increase respondent burden. Therefore, one potential approach would be to randomize respondents to complete only selected measures. However, to achieve the randomization, the sample sizes of ANOVA groups should be approximately equal (if equal sample sizes for the measures) or proportionally the same (if unequal sample sizes for the measures) for the measures, so that their Fstatistics are comparable.
Finally, when evaluating the statistical significance of the RV, it is important to recognize that a low power increases the risk of failing to detect clinically important differences, and that a very large power could convey statistical significance upon clinically trivial differences. Therefore, differences in measures should always be considered clinically, for example, by accounting for the proportions of patients misclassified using the different PRO measures.
Consent
Written informed consent was obtained from the patient for publication of this report.
Abbreviations
 RV:

Relative validity
 PRO:

Patientreported outcome
 CI:

Confidence interval
 SE:

Standard error
 ANOVA:

Analysis of variance
 CKD:

Chronic kidney disease
 QDISCKD:

Qualityoflife disease impact scale for chronic kidney disease
 KDQOL:

Kidney disease qualityoflife
 SF12:

Short Form 12
 PF:

Physical functioning
 RP:

Role physical
 BP:

Bodily pain
 GH:

General health
 VT:

Vitality
 SF:

Social functioning
 RE:

Role emotional
 PCS:

Physical component summary
 MCS:

Mental component summary
 MH:

Mental health
 IRT:

Item response theory
Declarations
Acknowledgement
The SBIR grant “Functional Health Computer Adaptive Test (CAT) in Chronic Kidney Disease” (5R44DK625553) was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (CoInvestigators: JE Ware and K Meyer). The National Kidney Foundation encouraged participants in its Kidney Early Evaluation Program (KEEP) to complete online questionnaires used to develop the new QDISCKD and patients of Dialysis Clinic, Inc. participated in focus groups and provided data for the clinical validation study. The John Ware Research Group (JWRG) Incorporated and Tufts Medical Center supported the clinical validation study out of their own research funds.
We are greatly indebted to the two anonymous reviewers for their valuable comments and constructive suggestions, which has strengthened our study considerately. We thank Magdalena Harrington and Mikel Strom for their assistance with the dataset. The opinions are those of authors and do not necessarily reflect the views of supporting organizations.
Authors’ Affiliations
References
 McHorney CA, Ware JE Jr, Rogers W, Raczek AE, Lu JFR: The validity and relative precision of MOS short and long form Health Status Scales and Dartmouth COOP Charts: Results from the Medical Outcomes Study. Medical Care 1992,30(Suppl 5):MS253MS265.PubMed
 Fayers MP, Machin D: Quality of life: The assessment, analysis and interpretation of patientreported outcomes. Chichester, England: Wiley; 2007.View Article
 Luo N, Johnson JA, Shaw JW, Coons SJ: Relative efficiency of the EQ5D, HUI2, and HUI3 index scores in measuring health burden of chronic medical conditions in a population health survey in the United States. Medical Care 2009, 47: 53–60. 10.1097/MLR.0b013e31817d92f8PubMedView Article
 Liang MH, Fossel AH, Larson MC: Comparisons of five health status instruments for orthopedic evaluation. Med Care 1990, 7: 632–642.View Article
 Kosinski M, Keller SD, Ware JE Jr, Hatoum HT, Kong SX: The SF36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: Relative validity of scales in relation to clinical measures of arthritis severity. Medical Care 1999,37(Suppl 5):MS23MS39.PubMed
 Werneke M, Hart DL: Discriminant validity and relative precision for classifying patients with nonspecific neck and back pain by anatomic pain patterns. Spine 2003, 28: 161–166. 10.1097/0000763220030115000012PubMedView Article
 Efron B, Tibshirani R: Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Statistical Science 1986, 1: 54–75. 10.1214/ss/1177013815View Article
 Efron B, Tibshirani R: Statistical data analysis in the computer age. Science 1991, 253: 390–395. 10.1126/science.253.5018.390PubMedView Article
 Efron B, Tibshirani R: An introduction to the bootstrap. New York: Chapman & Hall; 1993:1–436.View Article
 Henderson AR: The bootstrap: A technique for datadriven statistics. Using computerintensive analyses to explore experimental data. Clin Chim Acta 2005, 359: 1–26. 10.1016/j.cccn.2005.04.002PubMedView Article
 Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB: Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 1994,3(5):329–338. 10.1007/BF00451725PubMedView Article
 Ware JE Jr, Kosinski M, Keller SD: A 12item shortform health survey: Construction of scales and preliminary tests of reliability and validity. Medical Care 1996, 34: 220–233. 10.1097/0000565019960300000003PubMedView Article
 Lin P, Ware JE Jr, Meyer K, Richardson M, Bjorner JB: Methods for psychometric and clinical evaluations of CATbased measures of disease impact in chronic kidney disease (CKD). Value Health 2010,13(7):A244.View Article
 Ware JE Jr, Guyer R, Harrington M, Boulanger R: Evaluation of a more comprehensive survey item bank for standardizing diseasespecific impact comparisons across chronic conditions. Budapest, Hungary: Invited presentation at International Society for Quality of Life Research (ISOQOL) conference; 2012.
 Evans RW, Manninen DL, Garrison LP Jr, Hart LG, Blagg CR, Gutman RA, Hull AR, Lowrie EG: The quality of life of patients with endstage renal disease. N Eng J Med 1985,312(9):553–559. 10.1056/NEJM198502283120905View Article
 Evans RW, Rader B, Manninen DL: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin, Cooperative Multicenter EPO Clinical Trial Group. J Am Med Assoc 1990, 263: 825–830. 10.1001/jama.1990.03440060071035View Article
 Hansen RA, Chin H, Blalock S, Joy MS: Predialysis chronic kidney disease: evaluation of quality of life in clinic patients receiving comprehensive anemia care. Res Social Adm Pharm 2009,5(2):143–153. 10.1016/j.sapharm.2008.06.004PubMed CentralPubMedView Article
 Kerlinger FN: Foundations of behavioral research. New York: Holt, Rinehart, & Winston; 1973.
 Raczek AE, Ware JE Jr, Bjorner JB, Gandek B, Haley SM, Aaronson NK, Apolone G, Bech P, Brazier JE, Bullinger M, Sullivan M: Comparison of Rasch and summated rating scales constructed from SF36 physical functioning items in seven countries: Results from the IQOLA project. J Clin Epidemiol 1998, 51: 1203–1214. 10.1016/S08954356(98)001127PubMedView Article
 McHorney CA, Haley SM, Ware JE Jr: Evaluation of the MOS SF36 physical functioning scale (PF40): II, Comparison of relative precision using Likert and Rasch scoring methods. J Clin Epidemiol 1997, 50: 451–461. 10.1016/S08954356(96)004246PubMedView Article
 Fitzpatrick R, Norquist JM, Dawson J, Jenkinson C: Rasch scoring of outcomes of total hip replacement. J Clin Epidemiol 2003,56(1):68–74. 10.1016/S08954356(02)005322PubMedView Article
 Norquist JM, Fitzpatrick R, Dawson J, Jenkinson C: Comparing alternative Raschbased methods vs raw scores in measuring change in health. Medical Care 2004,42(1 Suppl):I25I36.PubMed
 Fitzpatrick R, Norquist JM, Jenkinson C, Reeves BC, Morris RW, Murray DW, Gregg PJ: A comparison of Rasch with Likert scoring to discriminate between patients' evaluations of total hip replacement surgery. Qual Life Res 2004,13(2):331–338.PubMedView Article
 Hart DL, Mioduski JE, Stratford PW: Simulated computerized adaptive tests for measuring functional status were efficient with good discriminant validity in patients with hip, knee, or foot/ankle impairments. J Clin Epidemiol 2005, 58: 629–638. 10.1016/j.jclinepi.2004.12.004PubMedView Article
 Hart DL, Cook KF, Mioduski JE, Teal CR, Crane PK: Simulated computerized adaptive test for patients with shoulder impairments was efficient and produced valid measures of function. J Clin Epidemiol 2006, 59: 290–298. 10.1016/j.jclinepi.2005.08.006PubMedView Article
 Deng N, Ware JE Jr: Using bootstrap confidence interval to compare relative validity coefficient: an example with PRO measures of chronic kidney disease impact. Value in Heal 2012,15(4):A159.View Article
 Efron B: Better bootstrap confidence intervals. J Am Stat Assoc 1987, 82: 171–200. 10.1080/01621459.1987.10478410View Article
 DiCiccio TJ, Efron B: Bootstrap confidence intervals. Statistical Science 1996, 11: 189–228.View Article
 R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2011. URL http://www.Rproject.org/
 Canty A, Ripley B: boot: Bootstrap R (SPlus) functions. R package version 1.3–4. 2012.
 Davison AC, Hinkley DV: Bootstrap methods and their applications. Cambridge: Cambridge University Press; 1997.View Article
 McHorney CA, Ware JE Jr, Raczek AE: The MOS 36item ShortForm health survey (SF36): II. psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care 1993,31(3):247–263. 10.1097/0000565019930300000006PubMedView Article
 Vickrey BG, Hays RD, Genovese BJ, Myers LW, Ellison GW: Comparison of a generic to diseasetargeted healthrelated qualityoflife measures for multiple sclerosis. J Clin Epidemiol 1997, 50: 557–569. 10.1016/S08954356(97)000012PubMedView Article
 Ware JE Jr, Kosinski M, Bjorner JB, Bayliss MS, Batenhorst A, Dahlöf CG, Tepper S, Dowson A: Applications of computerized adaptive testing (CAT) to the assessment of headache impact. Qual Life Res 2003,12(8):935–952. 10.1023/A:1026115230284PubMedView Article
 Carpenter J, Bithell J: Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Statistics In Medicine 2000, 19: 1141–1164. 10.1002/(SICI)10970258(20000515)19:9<1141::AIDSIM479>3.0.CO;2FPubMedView Article
 Lindman HR: Analysis of variance in complex experimental designs. New York, NY: W. H. Freeman; 1974.
 Box GEP: Some theorems on quadratic forms applied in the study of analysis of variance problems: II Effect on inequality of variance and correlation of errors in the twoway classification. Annals of Mathematical Statistics 1954, 25: 484–498. 10.1214/aoms/1177728717View Article
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.